WOODCLIFF LAKE, N.J., July 9 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that it will commence shipment of 12.5mg and 25mg meclizine HCl tablets immediately. At this time, Par believes it is the exclusive supplier of the AB-rated generic product.
Par marketed meclizine prior to an explosion at the facility of its API supplier in February 2008. Par has since qualified a new API source and received the appropriate approval of its supplemental new drug application to manufacture and market meclizine HCl utilizing its new API supplier.
Important information about meclizine
Meclizine is an oral antiemetic indicated for the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. It is contraindicated in individuals who have shown a previous hypersensitivity to it.
About Par Pharmaceutical
Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to risks and uncertainties, including the extent and impact of litigation arising out of the accounting issues described in the Company's filings with the Securities and Exchange Commission (SEC), the difficulty of predicting FDA filings and approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, uncertainty of patent litigation filed against the Company, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks and uncertainties detailed from time to time in the company's filings with the SEC, such as the Company's reports on Form 10-K, Form 10-Q and Form 8-K, and amendments thereto. Any forward-looking statements included in this press release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.
CONTACT: Allison Wey of Par Pharmaceutical Companies, Inc.,
+1-201-802-4000
Web site: http://www.parpharm.com/
